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Abstract
Replacement of growth hormone (GH) in patients suffering
from GH deficiency (GHD) offers clinical benefits on body
composition, exercise capacity, and skeletal integrity. How-
ever, GH replacement therapy (GHRT) is also associated
with insulin resistance, but the mechanisms are incomplete-
ly understood. We demonstrate that in GH-deficient mice
(growth hormone-releasing hormone receptor (Ghrhr)lit/lit),
insulin resistance after GHRT involves the upregulation of
the extracellular matrix (ECM) and the downregulation of
microRNA miR-29a in skeletal muscle. Based on RNA
deep sequencing of skeletal muscle from GH-treated
Ghrhrlit/lit mice, we identified several upregulated genes
as predicted miR-29a targets that are negative regulators
of insulin signaling or profibrotic/proinflammatory compo-
nents of the ECM. Using gain- and loss-of-function studies,
five of these genes were confirmed as endogenous targets
of miR-29a in human myotubes (PTEN, COL3A1, FSTL1,
SERPINH1, SPARC). In addition, in human myotubes,
IGF1, but not GH, downregulated miR-29a expression
and upregulated COL3A1. These results were confirmed
in a group of GH-deficient patients after 4 months of
GHRT. Serum IGF1 increased, skeletal muscle miR-29a
decreased, and miR-29a targets were upregulated in pa-
tients with a reduced insulin response (homeostatic model
assessment of insulin resistance (HOMA-IR)) after GHRT.
We conclude that miR-29a could contribute to the metabol-
ic response of muscle tissue to GHRT by regulating ECM
components and PTEN. miR-29a and its targets might be
valuable biomarkers for muscle metabolism following GH
replacement.
Key messages
& GHRT most significantly affects the ECM cluster in skel-
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& GHRT downregulates miR-29a and upregulates miR-29a
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& PTEN, COL3A1, FSTL1, SERPINH1, and SPARC are
endogenous miR-29a targets in human myotubes.
& IGF1 decreases miR-29a levels in human myotubes.
& miR-29a and its targets are regulated during GHRT in
skeletal muscle from humans.
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Growth hormone (GH) is an anabolic hormone that in-
creases skeletal muscle mass and bone density [1]. GH
action involves, however, also a catabolic effect on fat mass
through the upregulation of lipolysis, mainly at the level of
the visceral fat depot [2]. These opposing roles of GH
might serve as an important mechanism to prevent muscle
and bone catabolism during periods of limited caloric in-
take. The regulation of glucose homeostasis by GH is also
determined by GH effects on hepatocytes leading to elevat-
ed circulating IGF1 levels and increased glycogenolysis [3]
and gluconeogenesis [4]. These complex metabolic effects
of GH impose challenges on controlling cardiovascular risk
factors in patients suffering from adult-onset GH deficiency
(GHD). Patients with GHD have increased frequency of
adverse metabolic features such as increased abdominal
obesity, insulin resistance, and dyslipidemia [5]. Although
short-term GH replacement therapy (GHRT) improves
some of these risk factors such as visceral fat mass and
hypercholesterolemia, it can also aggravate insulin resis-
tance [6]. Long-term GHRT over 10 years was not able to
prevent an increase in the prevalence of the metabolic syn-
drome compared to baseline, despite improvements of LDL
cholesterol [7], and discontinuing long-term GHRT was
shown to lead to improved insulin sensitivity [8]. A more
detailed understanding of the mechanisms that contribute to
altered glucose homeostasis during GHRT is needed to pre-
vent adverse metabolic events and to optimize cardiovas-
cular risk factors during GHRT, for example, by tailoring
lifestyle interventions or adjunct pharmacological proto-
cols. Skeletal muscle is an important target tissue for such
interventions since it is the major contributor to postpran-
dial insulin-dependent glucose disposal. Moreover, a de-
creased response to insulin in muscle tissue is frequently
observed in humans during GHRT [9].
MicroRNAs (miRNAs) are a family of non-coding RNAs
of only 20–24 nucleotides in length. miRNAs have several
characteristics which make them important tools for the iden-
tification of disease mechanisms. A single miRNA can coor-
dinately regulate the expression of multiple genes involved in
different pathways, and therefore, the discovery of altered
miRNA expression could unravel gene regulation in complex
diseases. Furthermore, miRNAs have remarkable tissue spec-
ificity and might be more versatile markers of disease states
than protein-coding mRNAs [10]. We therefore hypothesized
that miRNA expression in skeletal muscle can help elucidate
the mechanisms that contribute to increased insulin resistance
after GHRT. Previously, miRNAs have been shown to cause
insulin resistance in liver and fat tissue as demonstrated by
global miRNA knockout models [11] or pharmacological
miRNA inhibitors [12]. Accordingly, the search for miRNAs
that are regulated in insulin-resistant states could also provide
novel strategies to treat cardiovascular risk factors during
GHRT.
Employing an animal model of GHD allowed us to identify
the regulation of miR-29a and several of its targets during
GHRT and to provide novel insights into the regulation of
muscle metabolism during GHRT in both animals and
humans.
Research design and methods
Participants
Muscle biopsies from 10 patients with adult-onset GHD for at
least 12months (three women, sevenmen, and age range 24 to
62 years) were recruited from a previously reported trial at the
University of Bern, Switzerland [13]. Three patients had
craniopharyngiomas, three patients had hormone-inactive pi-
tuitary adenomas, one patient had a Rathke’s cleft cyst, one
patient had traumatic hypopituitarism, one patient had a
macroprolactinoma, and one patient had hypophysitis. Inclu-
sion and exclusion criteria have been described in detail pre-
viously [13]. Biopsies were harvested from the middle portion
of the right tibialis anterior muscle under local anesthesia be-
fore and after a total of 4 months of GHRT [13]. Homeostatic
model assessment of insulin resistance (HOMA-IR) was cal-
culated as fasted insulin (μU/ml)×fasted glucose (mmol/l)/
22.5. FSTL1 and SPARC were measured in EDTA plasma
obtained in the fasted state after 1:120 dilution in PBS using
ELISAs from Uscn Life Science Inc.
A second cohort of participants was recruited from the
University of Leipzig, Germany [14]. Patients of either sex
referred to the University of Leipzig Heart Center, Germany,
were invited to participate if they displayed impaired fasting
glucose (>6.0 and <7.0 mmol/l with HbA1C <6 %) or im-
paired glucose tolerance (>7.8 and <11.1 mmol/l) 2 h after
oral intake of 75 g glucose and angiographic evidence of cor-
onary artery disease (>50 % stenosis diameter in at least one
major epicardial artery). Vastus lateralis muscle biopsies were
obtained under local anesthesia and immediately snap frozen
in liquid nitrogen. Seventy-five-gram oral glucose tolerance
tests (OGTT) were performed under standardized conditions.
In total, muscle biopsies from 33 patients (27 males, 6 fe-
males) were analyzed. We calculated the metabolic clearance
rate (MCR) (19.240−0.281×BMI−0.00498× Ins120−
0.333×Gluc120) and the insulin sensitivity index (ISI)
(0.222−0.00333×BMI−0.0000779×Ins120−0.000422×
age) from the OGTT since they correlate well with insulin
sensitivity as measured by the glucose clamp technique (r
values of 0.79 for MCR and ISI, respectively [15]). Average
age was 62.1±1.1 years, BMI 30.4±0.7 kg/m2, and glucose
during OGTT at 0 h was 6.1±0.1 mM, at 1 h 11.7±0.4 mM,
and at 2 h 9.1±0.3 mM. All values are means with SEM.
For isolation of muscle cells, human skeletal muscle was
obtained from elective surgery of the lower limb performed on
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two healthy donors (males, age 20 and 22 years, BMI 22 kg/
m2) at the University Hospital of Zurich.
All study protocols were approved by the local ethics com-
mittees. All subjects gave written informed consent before
enrollment.
Animals
All mice were maintained in a 12-h light/dark cycle in a
pathogen-free animal facility. C57BL/6J-growth hormone-
releasing hormone receptor (Ghrhr)lit/J mice were purchased
from Jackson Laboratories. Between 10 and 14 weeks of age,
mice were injected once daily with recombinant GH subcuta-
neously (Genotropin, Pfizer) at a dose of 6 μg/g bodyweight
per day. We chose this dosage since 6 μg/g bodyweight in-
duced insulin resistance in GHD mice in a previous report
[16]. After 21 days, mice were sacrificed and the tibialis
anterior and soleus muscle and liver tissue removed, snap
frozen in liquid nitrogen, and stored at −80 °C. Serum was
collected from tail-vein blood and analyzed for glucose using
FreeStyle Lite (Abbott) and for insulin using the ultrasensitive
mouse insulin ELISA kit (Crystal Chem). C57BL6/6J mice
were purchased from Harlan Laboratories. Starting at 4 weeks
of age, mice were fed a 58 % fat and sucrose diet (D12331;
Research Diets, USA). After 20 weeks, mice were sacrificed
and the tibialis anterior muscle removed and processed as
described above. All animal studies were approved by the
ethics committee of the Kantonale Veterinäramt Zürich, and
the principles of laboratory animal care were followed.
RNA isolation, qRT-PCR, and mRNA sequencing
Total RNAwas isolated from muscle tissues using the TRIzol
reagent (Invitrogen). For quantitative reverse transcription
(qRT)-PCR, total RNA was subjected to DNAse digestion
followed by complementary DNA preparation with random
hexamer primers using Super Script III Reverse Transcriptase
(Invitrogen). Messenger RNA (mRNA) was analyzed by
quantitative real-time PCR using the FastStart Universal
SYBR Green Master Mix (Roche) with a 7500 FastStart
Real-Time PCR system (Applied Biosystems). Transcript
levels were normalized to 18S ribosomal RNA. Primer se-
quences are provided in ESM 1: Table S6. miRNA levels were
measured using qRT-PCR with the TaqMan miRNA assays
(Applied Biosystems). The ubiquitous miR-let-7 was used as
an endogenous control based on its stable expression in all
samples and its conservation between mice and humans. For
mRNA and small RNA profiling, RNA was subjected to
Illumina deep sequencing using a service from LC Sciences
(Houston, TX, USA). The sequence results were obtained as
FPKM (fragment per kilobase of exons per million reads) for
each transcript.
Primary human myotube cultures, miRNA transfection,
and western blotting
Human skeletal muscle tissue was subjected to collagen di-
gestion, and myogenic progenitor cells were isolated using
flow cytometry based on CD56 expression and the absence
of CD15, CD31, and CD45 staining. Cells were grown on
collagen-coated plates in culture medium (1:1 v/v F10 nutrient
mixture and Dulbecco’s modified Eagle’s medium (DMEM)
low glucose containing 20 % fetal bovine serum (FBS), 1 %
penicillin/streptomycin (P/S), and 5 ng/ml basic FGF). Exper-
iments were always performed on two independent primary
muscle cell cultures obtained from the two healthy donors and
analyzed in different passages (not higher than passage 10),
e.g., n=4, indicating two different passages each from the two
independent primary cultures. Differentiation was initiated
when myoblasts reached subconfluency by changing the me-
dia to DMEM containing 2 % horse serum and 1 % P/S. IGF1
was measured in the supernatant using an ELISA for human
IGF1 from Abcam. miRNA transfection was performed on
human myotubes at day 4 of differentiation using Lipofecta-
mine RNAimax (Invitrogen) and human miRNA mimics
(38 nM, Mission; Sigma-Aldrich) or miRNA inhibitors
(12 nM, antagomirs [17]). Concentrations of oligonucleotides
were chosen based on dose-response curves and miR-29a tar-
get gene expression in human myotubes (data not shown).
Scrambled mimics or antagomirs were used as controls. Cells
were harvested for RNA isolation 24 or 48 h after transfection
using the TRIzol reagent (Invitrogen). Myotubes were incu-
bated for the indicated time points with IGF1 or GH.We chose
1 μg/ml GH according to previous reports that demonstrated
500–1000 ng/ml GH to havemaximal effects on GH signaling
in myoblasts and myotubes [18–20]. For IGF1 incubations,
we chose 76 ng/ml (10 nM), a concentration for which Baudry
et al. [21] demonstrated maximal effects on glucose uptake
and IGF1 signaling in myotubes. For western blotting,
myotubes were lysed in RIPA buffer and separated by SDS-
PAGE, transferred to PVDFmembranes, and primary antibod-
ies were used to detect myosin heavy chain (MHC, MF-20,
DSHB), GAPDH (Proteintech, #10494), AKT, and phospho-
AKT (Cell Signalling, #2920, #4058).
Statistical analyses
Data shown as arbitrary units (AU) are normalized to the
average value of the control group. Groups were compared
using Student’s t test in Excel software. Correlation and
ANOVA analysis was performed using the GraphPad Prism
software. Fold-change regulations were analyzed using one-
sample t test with the hypothetical means of 1 using the
GraphPad Prism software. P values smaller than 0.05 were
considered significant. Results are shown as means±SEM.
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Results
To elucidate the mechanisms that regulate muscle metabolism
during GHRT, we chose Ghrhrlit/lit mice as a model for GHD.
Ghrhrlit/lit mice are homozygous for a missense mutation in
the growth hormone-releasing hormone receptor (Ghrhr)
resulting in pituitary and serum Gh levels of less than 5 %
and serum IGF1 levels of 15–20 % of normal [22]. As expect-
ed from previous protocols [16], 3 weeks of GHRT induced
insulin resistance in the Gh-deficient mice compared to saline
injections as demonstrated by increased fasting and random
glucose values and higher insulin levels (Fig. 1a). GHRT also
increased bodyweight (data not shown). To identify relevant
changes in gene expression that could affect insulin sensitivity
in skeletal muscle, we performed next-generation sequencing
on total RNA isolated from muscle tissue from GHD mice
with or without GHRT. The GH treatment significantly regu-
lated 1422 transcripts (1063 upregulated and 360 downregu-
lated, ESM 1: Table S1). Strikingly, the three most significant-
ly induced functional clusters in the GHRT group involved
extracellular matrix (ECM) organization, while the three func-
tional clusters with the most significant downregulation in-
cluded fatty acid metabolism (Fig. 1b). To identify novel
mechanisms for the regulation of ECM during GHRT, we
turned to the miR-29 microRNA family (miR-29a, miR-29b,
and miR-29c) which is a well-known regulator of ECM [23].
Small RNA sequencing identified miR-29a as the most abun-
dant member of the miR-29 family in skeletal muscle from
mice and humans and in muscle groups with either predomi-
nant fiber type I (M. soleus) or fiber type II (M. tibialis ante-
rior, M. fibularis brevis, M. rectus femoris) (Fig. 1c). Impor-
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Fig. 1 GHRT regulates miR-29a expression in skeletal muscle from
GHD mice. GHD mice were treated with PBS or GH for 3 weeks and
serum samples and tibialis anterior and soleus muscle harvested. a Blood
glucose and serum insulin levels in GHD mice with (GH) or without
(PBS) 3 weeks of GHRT. b Total RNA isolated from tibialis anterior
muscle from GHD mice treated with PBS or GH was analyzed using
RNA deep sequencing. The three most significantly regulated functional
clusters are depicted for the group of genes that are increased after GHRT
(GHT>PBS) or decreased (GHT<PBS). cRNA frommouse soleus mus-
cle (M.Sol), tibialis anterior muscle (M.TA), or lower leg muscles from
two healthy human subjects (M. rectus femoris and M. fibularis brevis,
respectively) was analyzed using small RNA deep sequencing and results
expressed as percent of all detected miRNA sequences. n=2 for
eachmuscle group. d qRT-PCR analysis of miR-29a in RNA from tibialis
anterior muscle normalized to miR-let-7 and shown as arbitrary units
(AU). Analysis was performed in the same mice as described in a. e All
predicted miR-29a targets that are conserved between mice and humans
and upregulated by GH in the RNA sequencing data described in b ≥2-
fold shown as FPKM (fragments per kilobase of exons per million
fragments mapped). Selected targets as described in the text are pointed
out by arrows. f qRT-PCR analysis of gene expression in skeletal muscle
after GH (gray) or PBS treatment (white). mRNAwas normalized to 18S
RNA and shown as AU. Results (a, d, f) show combined data for male
and female mice (n=7 for GH and n=8 for PBS) and were analyzed using
Student’s t test. *p<0.05, ***p<0.001
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GHRT treated mice in both type I (M. soleus) and type II (M.
tibialis anterior) muscle types (Fig. 1d). We then searched for
all predicted miR-29a targets in the group of upregulated
genes from our sequencing data that are conserved between
mice and humans using the TargetScan program [24] (ESM 1:
Table S2). Importantly, the list of predicted targets that were
≥2-fold upregulated was enriched for profibrotic and proin-
flammatory genes that are part of the ECM (Fig. 1e and ESM
1: Table S3), and we chose five candidates from the 10 highest
expressed genes (COL3A1, FSTL1, COL6A3, SERPINH1,
SPARC). We selected COL3A1 and COL6A3 from the seven
collagen isoforms among these genes, because their upregu-
lation has consistently been shown to correlate with skeletal
muscle insulin resistance in humans [25, 26]. From the list of
miR-29a targets that were upregulated less than twofold, we
selected PTEN since it is a well-established inhibitor of the
intracellular insulin signaling [27]. The regulation of these
selected predicted miR-29a targets during GHRT was con-
firmed using qRT-PCR (Fig. 1f). Together, these data identify
miR-29a and a set of its targets that could contribute to the
changes in glucose tolerance during GHRT.
To test whether the confirmed targets of miR-29a could
also be relevant for human skeletal muscle, we transfected
miR-29a mimics or inhibitors (antagomirs) into human
myotubes from two healthy donors. A significant repression
or induction of miRNA targets at the mRNA level was
reached after 48 h of mimic or inhibitor (antagomirs) transfec-
tion, respectively, with a substantial decrease of mRNA re-
pression already observed after 24 h (Fig. 2). As expected,
the effect of miR-29a inhibition was in general weaker than
that of the overexpression, given that endogenous miR-29a
levels are lower than the supra-physiological overexpression
with the mimics. Overexpression or inhibition of miR-29a did
not change morphology or differentiation state of the
myotubes as evaluated by light microscopy (data not shown)
and expression of MHC protein (ESM 1: Fig. S1). Also,
insulin-stimulated AKT phosphorylation was unaltered indi-
cating that miR-29a targets do not induce insulin resistance in
human muscle cells in a cell autonomous manner (ESM 1:
Fig. S1). Overall, our approach validated five of the six pre-
dicted miR-29a targets as endogenous targets in differentiated
human skeletal muscle cells (PTEN, COL3A1, FSTL1,
SERPINH1, SPARC).
To test whether the regulation of miR-29a in skeletal mus-
cle was directly related to the GHRT, we incubated human
myotubes with either GH or IGF1. Liver is the major source
of GH-stimulated circulating IGF1 levels [28], but GH also
stimulates IGF1 mRNA levels in extrahepatic tissues such as
skeletal muscle [29]. However, we did not detect significant
IGF1 levels in the supernatant from human myotubes upon
GH incubation (data not shown), indicating that the effects of
GH and IGF1 can be addressed separately in these cells. We
found that IGF1, but not GH, gradually decreased miR-29a
levels over the course of 48 h (Fig. 3a). Furthermore, CO-
L3A1 expression was reversely correlated to miR-29a levels
(Fig. 3b). Other confirmed miR-29a targets were not signifi-
cantly regulated (data not shown) and might need longer in-
cubation times or a more pronounced downregulation of miR-
Fig. 2 Target gene regulation in
human myotubes by miR-29a.
Human myotubes were
transfected with miR-29a mimics
or antagomirs or the respective
scrambled controls. After the
indicated time intervals, cells
were harvested for RNA isolation.
Results are shown for qRT-PCR
analysis after miR-29a mimic
transfection (gray) compared to
control (white), n=4, or after
antagomir-29a transfection (gray)
compared to control (white), n=
4–5. Results were normalized to
18S RNA and shown as arbitrary
units (AU). Student’s t test was
used to compare the two groups.
*p<0.05, **p<0.01, ***p<0.001
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29a as observed for the adult skeletal muscle in vivo. We
conclude that downregulation of miR-29a in skeletal muscle
during GHRT could be a direct consequence of increased
IGF1 levels.
To understand whether the regulation of miR-29a and its
targets is important for the change in insulin sensitivity during
GHRT in humans, we studied a cohort of GHD patients that
received GHRT over 4 months. We used HOMA-IR to group
the patients with an increase or decrease in insulin sensitivity
(IS) after GHRT. As expected, insulin levels negatively corre-
lated to IS in that patients with decreased IS also had signifi-
cantly higher insulin levels (increased HOMA-IR) (Table 1).
Furthermore, triglyceride levels were significantly higher in
the insulin-resistant group after GHRT compared to patients
with improved insulin sensitivity. We further analyzed the
impact of GHRT on IGF1 and miR-29a levels compared to
the baseline levels of the participants. GHRT significantly in-
duced serum IGF1 levels and decreased miR-29a expression
in skeletal muscle (Fig. 4a). Importantly, a significant induc-
tion of IGF1 and downregulation of miR-29a was observed in
the subgroup of patients with increased HOMA-IR, but not
with decreased HOMA-IR (Fig. 4a). In addition, we found a
striking correlation between the decrease of miR-29a levels
and the change of insulin sensitivity during GHRT (Fig. 4b).
We conclude that downregulation of miR-29a in skeletal mus-
cle after GHRT is related to the increase in serum IGF1 and
correlates with the change in insulin sensitivity.
Next, we analyzed the five validated miR-29a targets in the
GHRT human cohort. We observed a significant induction of
these target genes after GHRT confirming a conserved role of
these genes in our animal model of GHRT and the patients
(Fig. 5a). To assess the contribution of miR-29a to the regu-
lation of these genes, we separately analyzed their regulation
in the subgroups with improved insulin sensitivity (HOMA-
IR decreased) or decreased insulin sensitivity (HOMA-IR in-
creased). Importantly, a significant miR-29a target upregula-
tion was only observed in subjects who developed insulin
resistance (Fig. 5a), consistent with the significant downregu-
lation of miR-29a in this group. We conclude that miR-29a
could contribute to the effects of GHRT on skeletal muscle
insulin resistance by participating in the regulation of intracel-
lular insulin signaling and remodeling of the ECM (Fig. 5b).
To test whether regulation of miR-29a in skeletal muscle
also occurs in insulin resistance associated with obesity, we
investigated muscle biopsies from both a cohort of prediabetic
patients with abnormal OGTT and an average BMI of 30.4±
0.7 kg/m2 as well as in mice fed a high-fat diet (HFD). How-
ever, miR-29a did not correlate with the metabolic clearance
rate (MCR) or insulin sensitivity index (ISI) in the 33 insulin-
resistant subjects (ESM 1: Fig. S2). In mice, HFD led to an
increase in fasted and random blood glucose, but miR-29a
levels were not altered in skeletal muscle (ESM 1: Fig. S3).
We also did not detect any differences in miR-29a target gene
expression in skeletal muscle from HFD mice (ESM 1:
Fig. S3). These data show that miRNA regulation and gene
expression in skeletal muscle after GHRT differs from
obesity-associated insulin resistance.
Discussion
This is the first study to report altered miRNA expression
during GHRT. Using next-generation sequencing, we identify
the ECM cluster as the most significant upregulated group of
genes in skeletal muscle following GH treatment ofGhrhrlit/lit
mice. Next, by performing small RNA sequencing, we dem-
onstrate that miR-29a is the most abundant member of the
miR-29 family in skeletal muscle and that its expression is
decreased during GHRT. Furthermore, we validate five genes
as targets of miR-29a in both mice and human myotubes. One
of these genes, PTEN, is a known suppressor of insulin sig-
naling while the remaining four genes are all involved in ECM
remodeling. These results are corroborated in human patients
Fig. 3 IGF1, but not GH, downregulates miR-29a levels in human
myotubes. a Human myotubes were incubated for the indicated time
intervals with 1 μg/ml GH or 76 ng/ml (10 nM) IGF1 before RNAwas
isolated. miR-29a levels were analyzed using qRT-PCR and normalized
to miR-let-7. n=4 for GH and n=10 for IGF1. bDirect comparison of the
effects of GH and IGF1 on miR-29a levels and COL3A1 expression after
48-h incubation in an independent set of experiments, n=3–5. Results are
shown as arbitrary units (AU). Changes in a were analyzed using
ANOVA and Dunnett’s post test comparing all samples to the control
samples (at 0 h). The effects of GH and IGF1 on miR-29a and COL3A1
levels (b) were analyzed using Student’s t test. *p<0.05, ***p<0.001
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where again we could demonstrate that miR-29a and its en-
dogenous targets are significantly regulated by GHRT in the
group of insulin-resistant patients. We therefore conclude that
miR-29a along with its targets could participate in muscle
insulin resistance following GHRT.
GH has a profound effect on the ECM and has been shown
to induce collagen synthesis in skeletal muscle [30]. The in-
duction of collagens in human skeletal muscle has been asso-
ciated with insulin resistance [25, 26, 31], and the increase in
ECM and collagens during GHRT might also negatively in-
fluence muscle metabolism. Our data support this notion since
GHRT in mice caused hyperinsulinemia and induced ECM
remodeling in skeletal muscle. In animal models, pharmaco-
logical or genetic ECM manipulation alters insulin sensitivity
in skeletal muscle [32, 33]. The accumulation of ECM in
skeletal muscle is linked to increased inflammation [25, 26]
and decreased insulin signaling [31] by the interaction of col-
lagens with integrins in endothelial cells and immune cells
leading to decreased muscle vascularization [34] and an in-
creased immune response [35]. miR-29a can further influence
the collagen matrix by targeting SERPINH1 (heat shock pro-
tein 47), which is important for maturation and secretion of
collagens [36], and SPARC (osteonectin, BM-40), which pro-
motes formation of collagen fibrils [37]. FSTL1 and SPARC
are also secreted from skeletal muscle into the circulation up-
on exercise and are considered myokines [38, 39]. Only four
myokines are regulated by GHRT according to our RNAseq
data (ESM 1: Table S4), and FSTL1 and SPARC show the
highest regulation. Importantly, both FSTL1 and SPARC are
linked to inflammation and insulin resistance. FSTL1 is a
proinflammatory cytokine that is increased in adipose tissue
of obese mice and in the serum of overweight and obese sub-
jects [40]. SPARC is a profibrotic protein that is increased in
adipose tissue from obese humans [41] and in plasma of
insulin-resistant women with gestational diabetes [42]. In
our study, we did not observe an induction of plasma FSTL1
or SPARC after GHRT (ESM 1: Fig. S4), which might require
stimulation with an acute exercise bout [38, 39]. Interestingly,
FSTL1 levels even decreased during GHRT, most pronounced
in the subgroup with a decrease in their insulin sensitivity
(ESM 1: Fig. S4), which deserves further testing. Increased
myokine secretion after exercise bouts during GHRTcould also
have beneficial effects, since increased SPARC levels after ex-
ercise suppressed colon tumorigenesis [38] and muscle-derived
FSTL1 attenuated neointimal formation in response to arterial
injury [43]. Together, we propose that disinhibition of ECM-
specific target genes of miR-29a could contribute to impaired
insulin signaling following GH treatment (Fig. 5b).
A possible mechanism by which GH might affect ECM
and miR-29a expression is through IGF1. One report links
GH treatment to muscle ECM synthesis and increases in
IGF1 levels in serum as well as mRNA in skeletal muscle
[44]. In our study, not only did IGF1 decrease miR-29a levels
in human myotubes but a significant reduction of skeletal
Table 1 Characteristics of the GHD patients at baseline and after 4 months of GHRT
IS increased p values
Start vs.
4 months





increased 4 monthsGHRT start GHRT 4 months GHRT start GHRT 4 months
Sex (n) 5 5
Male 4 3
Female 1 2
Age (years) 35.0±3.7 47.6±6.5 0.10
BMI (kg/m2) 27.1±1.3 27.4±1.5 0.63 25.5±0.8 25.6±1.0 0.70 0.30
Lean mass (kg) 55.7±5.0 57.8±5.4 0.13 56.1±7.8 60.3±8.8 0.09 0.79
Waist (cm) 93.8±3.3 93.1±3.9 0.53 95.9±4.5 94.0±4.9 0.29 0.88
Fasted glucose (mM) 4.6±0.3 4.6±0.3 0.56 4.6±0.3 5.1±0.1 0.13 0.07
Fasted insulin (mU/l) 4.8±1.5 3.0±1.4 0.01 5.0±1.1 7.8±1.6 0.02 0.03
HOMA-IR 1.0±0.4 0.7±0.4 0.01 1.1±0.3 1.8±0.3 0.01 0.04
IGF1 (μg/l) 104.8±20.9 175.2±23.6 0.06 93.0±24.3 180.4±29.0 0.01 0.88
Triglycerides (mM) 1.7±1.0 0.9±0.3 0.26 1.8±0.2 2.1±0.3 0.16 0.01
NEFA (mM) 0.5±0.1 0.6±0.1 0.78 0.7±0.1 0.7±0.0 0.58 0.12
Total cholesterol (mM) 4.9±0.5 4.8±0.9 0.92 5.5±0.4 5.0±0.4 0.07 0.83
LDL (mM) 3.4±0.3 3.3±0.8 0.86 3.9±0.4 3.4±0.4 0.01 0.85
HDL (mM) 1.2±0.1 1.4±0.1 0.18 1.2±0.1 1.2±0.1 0.86 0.25
Values shown are means±SEM
Significant p-values (p<0.05) are indicated in italic font style
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muscle miR-29a was only observed in the subgroup of
insulin-resistant patients with a significant increase in serum
IGF1. Our results support the conclusion that GH, through
IGF1 signaling, could induce expression of ECM components
partly by decreasing the expression of miR-29a. There is cur-
rently no evidence to support a major role of GH on fiber
typing [45] and the transcripts of the two major MHC iso-
forms in tibialis anterior muscle, Myh1 and Myh4, were not
regulated after GHRT in our animal model (ESM 1: Table S5).
The contribution of miR-29a to the regulation of its targets
during GHRT is best reflected in the divergent regulation of
these targets between the group of insulin-resistant patients
with decreased miR-29a levels compared to patients with im-
proved insulin sensitivity and no change in miR-29a levels
following GHRT. Although the effect of miR-29a on its tar-
gets is mild, the target regulation would be expected to occur
over a long period of time and thereby slowly contribute to the
deterioration of insulin signaling in skeletal muscle.
Moreover, we cannot rule out the possibility that miR-29a
targets additional proteins of the ECM during GHRT. The
downregulation of miR-29a could also impact the insulin re-
sponse in skeletal muscle by targeting intracellular regulators
of insulin signaling. Indeed, we identified PTEN as an endog-
enous target of miR-29a in human myotubes. PTEN is an
inhibitor of insulin signaling and its upregulation following
GHRTwould expect to decrease the insulin response in mus-
cle tissue [27]. However, most miR-29a targets are part of the
ECM and affect the interaction of myofibers with their milieu.
Indeed, overexpression or inhibition of miR-29a in human
myotubes in vitro did not alter insulin-induced AKT phos-
phorylation demonstrating that investigating the role of miR-
29a for muscle insulin resistance will depend on reducing
miR-29a levels in skeletal muscle in vivo.
We did not observe any correlation between miR-29a and
insulin sensitivity in obese humans or mice with diet-induced
obesity, indicating differences in mechanisms of insulin
Fig. 4 Increased serum IGF1 and decreased miR-29a levels in skeletal
muscle fromGHD patients with decreased insulin sensitivity after GHRT.
Ten GHD patients were subjected to GHRT for 4 months. a Changes in
serum IGF1 and miR-29a levels in biopsies from the tibialis anterior
muscle in GHD patients after 4 months of GHRT. Values are shown for
the whole cohort, n=10, or separately analyzed for individuals with
improved IS (HOMA-IR decreased), n=5, or worsened IS (HOMA-IR
increased), n=5, after GHRT. b Relationship between the change in
insulin sensitivity (ΔHOMA-IR) induced by 4 months of GHRT and
the change in miR-29a levels in skeletal muscle biopsies. The dashed
lines indicate the intercept points corresponding to a Δ value of 1, i.e.,
no change in HOMA-IR or miR-29a levels. miRNA levels were analyzed
by qRT-PCR and normalized to miR-let-7. Results are shown as fold
change of values after GHRT compared to values before GHRT.
*p<0.05, **p<0.01 (Student’s t test)
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resistance in skeletal muscle during GHRT and obesity. How-
ever, the average fasting insulin level in the prediabetic sub-
jects (0.141 nmol/l) might not have been high enough to acti-
vate the IGF1 receptor and affect miR-29a expression. In this
regard, it would be interesting to assess miR-29a regulation in
skeletal muscle from insulin-resistant or diabetic subjects with
a more pronounced hyperinsulinemia.
Recently, miR-29a was reported to be upregulated in
skeletal muscle from insulin-resistant mice fed HFD [46].
We and other groups [47, 48] did not find such an induc-
tion. Overall, we exclude a relevant regulation of miR-29a
in skeletal muscle of HFD mice not only by miRNA qRT-
PCR but also by the absence of any changes in the expres-
sion of miR-29a target genes. Potential explanations for the
discrepant results include the different response of C57BL6
substrains to HFD [49] or differences in the HFD itself.
Intriguingly, miR-29a was among the highest downregulat-
ed miRNAs in human skeletal muscle during a 3-h
hyperinsulinemic-euglycemic clamp [50]. The average in-
sulin concentration achieved during this clamp was slightly
above 1 nM and could have been sufficient to activate the
IGF1 receptor in skeletal muscle. Due to technical
limitations with the glucose clamp technique, we used
HOMA-IR as a surrogate to determine insulin sensitivity.
However, the significantly higher triglycerides in subjects
with increased HOMA-IR support a clinically meaningful
separation of the metabolic state in our study.
Compared to patients with improved insulin sensitivity fol-
lowing GHRT, miR-29a levels decreased in patients with dete-
riorated insulin sensitivity by 30 % (Fig. 4a). The impact of
such miRNA regulation that persists over long periods of time,
e.g., months, in vivo has not been experimentally validated yet.
However, regulation of less than twofold of miR-499 is associ-
ated with the induction of the type 1 muscle program in active
compared to sedentary human subjects [51] and a 40 % induc-
tion of miR-375 is associated with altered pancreatic beta cell
proliferation in obese mice [52]. Therefore, our data provide
strong support that regulation of miR-29a and its targets can
contribute to muscle insulin resistance.
Patients with GHD are very heterogeneous in terms of co-
morbidities, and the efficacy of GHRT on metabolic parame-
ters is highly variable. The identification of markers for ad-
verse metabolic effects of GHRT is therefore of clinical im-
portance. If future studies with larger sample size confirm our
Fig. 5 Regulation of miR-29a targets in human skeletal muscle after
GHRT. RNA was isolated from biopsies of the tibialis anterior muscle
obtained from the GHD patients described in Fig. 4. a qRT-PCR analysis
in skeletal muscle biopsies before (white) or after (gray) 4 months of
GHRT, n=9, or separately analyzed for HOMA-IR decreased, n=5, and
HOMA-IR increased groups, n=4. Results were normalized to 18S RNA
and shown as arbitrary units (AU). Student’s t test was used to compare
the two groups. *p<0.05. bHypothetical model demonstrating the role of
GHRT for ECM remodeling and its association with insulin resistance in
skeletal muscle. Decreased miR-29a levels and upregulation of its targets
during GHRT could contribute to this regulation
J Mol Med (2015) 93:1369–1379 1377
results, miR-29a and its targets could be valuable biomarkers
for a decreased insulin response in skeletal muscle during
GHRT and might, for example, help to identify other serum
factors than IGF1 that allow to non-invasively monitor the
metabolic response of skeletal muscle when GH is replaced.
Preclinical animal models for GHRTas described in our study
could be used to characterize in more detail the development
of insulin resistance and changes in exercise-induced plasma
levels of miR-29a-regulated myokines.
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